FDA Plans Reclassification of Diagnostic Endoscopic Light Source Systems Used in Bladder Cancer Detection
核心洞察
The FDA has communicated to Photocure ASA that it plans to issue a proposed order to reclassify diagnostic endoscopic light source systems (FDA Product Code OAY) under its own initiative.
The reclassification follows a petition submitted by Karl Storz SE & Co. KG (搜索) and is expected to proceed through established FDA processes in the second half of 2026.
Photocure's technology makes cancer cells glow bright pink and has been used to improve health outcomes for bladder cancer patients worldwide.
The U.S. Food and Drug Administration has informed Photocure ASA that it intends to reclassify diagnostic endoscopic light source systems under FDA Product Code OAY through its own regulatory initiative, the Norwegian bladder cancer technology company announced April 13, 2026.
The FDA communicated its plans to issue a proposed reclassification order under Section 513(f)(3) of the Federal Food, Drug, and Cosmetic Act as part of ongoing dialogue with Photocure. This development follows a reclassification petition submitted by Karl Storz SE & Co. KG (搜索), which Photocure previously addressed in a March 28, 2026 press release.
Regulatory Timeline and Process
The FDA intends to issue the proposed reclassification order in the second half of 2026, subject to internal agency processes. The reclassification will proceed through the FDA's established regulatory framework, with final determinations made by the agency following standard procedures.
The FDA's response to the original reclassification petition did not preclude the agency from pursuing reclassification under its own initiative, consistent with the current regulatory action being taken.
Impact on Bladder Cancer Technology
Photocure describes itself as "The Bladder Cancer Company" and has developed technology that makes cancer cells glow bright pink during diagnostic procedures. The company states this unique approach has led to better health outcomes for bladder cancer patients worldwide.
The reclassification of diagnostic endoscopic light source systems could affect the regulatory pathway for medical devices used in bladder cancer detection and diagnosis procedures. These systems play a critical role in endoscopic examinations where Photocure's fluorescence-based technology is employed to enhance visualization of cancerous tissue.
Company Background
Photocure ASA is headquartered in Oslo, Norway and trades on the Oslo Stock Exchange under the ticker PHO. The company focuses on delivering transformative solutions to improve the lives of bladder cancer patients through its proprietary diagnostic technology platform.